MANUFACTURING ARTICLES

MANUFACTURING VIDEOS

Ribonucleic acid technologies are often characterized as “plug and play” technologies, with inherent advantages in rapidity of early development of drug candidates, but how does the next wave of technologies challenge this assumption? In this Cell & Gene Live segment, panelists Nathaniel Wang, CEO and Co-Founder, Replicate Bioscience and Sam Deutch, EVP of Research and Early Development at Nutcracker Therapeutics, discuss the lessons that next generation RNA engineers take from previous iterations of the technology.

Is the future of RNA manufacturing fully enzymatic? In this Advancing RNA Live clip, panelists Claire MacCleod and Jill Caswell unpack why the "hybrid" chemoenzymatic approach is an essential bridge to an enzymatic future for siRNA production. 

This innovative approach holds promise for reducing the need for extensive clinical drug-drug interaction studies, potentially streamlining the drug development process.

In this Advancing RNA Live segment, several speakers raise concerns about the industry's ability to accurately measure impurities, particularly dsRNA, arguing that current analytics are insufficient, especially for high-dose therapeutics.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS